Plain-English answer
The zero-markup drug policy required public medical institutions to sell medicines without adding a profit markup. It was designed to break the link between prescribing and hospital drug revenue. The policy is one of the most important reforms in China's effort to reduce drug overuse and change public hospital incentives.
Policy context
China historically allowed hospitals to add a markup to drug procurement prices, often described as a 15 percent markup. This helped hospitals compensate for low service prices and limited subsidies but encouraged drug-centered revenue. The zero-markup policy began in primary-care reform and expanded across public hospitals as part of the post-2009 health reforms.
Operating model
Evidence on the policy is mixed and therefore useful. Studies show reductions in drug revenue shares, but also possible shifts toward other revenue sources or provider-induced demand. Removing drug profit does not automatically remove all incentives for overuse. Hospitals need replacement compensation through service prices, subsidies, payment reform, and salary reform.
Strategic reading
For companies, zero markup changed the economics of hospital pharmacy channels. Drug companies could no longer assume that hospital profit from dispensing would support uptake. The policy also explains why China later moved further into NRDL negotiation, centralized procurement, and payment reform: drug markup removal was necessary but not sufficient to control spending.
Decision test
For Zero Markup Drug Policy in China, the practical test is whether the analysis identifies the payer rule, hospital incentive, procurement route, affected product category, and implementation level. A page that only says China wants lower prices is not useful. The specific question is who changes behavior, under which rule, with what price, budget, quality, and access consequence.
Implementation detail
Zero Markup Drug Policy in China should be read through the full chain of Chinese healthcare finance: policy design, provincial or national implementation, hospital operating response, department-level behavior, and patient access. A reform can lower headline prices while still creating new questions about quality, supply, service availability, hospital incentives, and whether the savings reach patients in the form of usable care. The relevant evidence is therefore not only the announced policy, but also how hospitals, manufacturers, physicians, distributors, and insurers respond after implementation.
For market access, the page is most useful when it separates four layers. The first is the formal rule: who issued it, which products or services it covers, and when it applies. The second is the payment consequence: who loses margin, gains volume, absorbs cost, or changes budget risk. The third is the clinical consequence: whether physicians and hospitals can still choose the product, service, or workflow that fits the patient. The fourth is the commercialization consequence: whether a company should compete, differentiate, localize, redesign the channel, gather new evidence, or avoid the category. Without those layers, payment and procurement reform sounds abstract even though it directly determines adoption.